echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > The scope of drug centralized purchase was expanded to 25 regions, and the new regulations of "multiple winning bids" were introduced

    The scope of drug centralized purchase was expanded to 25 regions, and the new regulations of "multiple winning bids" were introduced

    • Last Update: 2019-09-02
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    [industry trends of pharmaceutical network] on September 1, Shanghai Sunshine pharmaceutical purchase network released a centralized drug purchase document in the alliance region According to the documents, the alliance area does not include the "4 + 7" pilot cities It is mainly aimed at the 25 regions of Shanxi, Inner Mongolia, Liaoning, Jilin, Heilongjiang, Jiangsu, Zhejiang, Anhui, Jiangxi, Shandong, Henan, Hubei, Hunan, Guangdong, Guangxi, Hainan, Sichuan, Guizhou, Yunnan, Xizang, Shaanxi, Gansu, Qinghai, Ningxia and Xinjiang It can be seen that the scope of centralized mining is obvious in these 25 regions Expand and gradually push forward to the whole country So, is there any difference between this centralized mining and "4 + 7"? It can be seen from the content of the document that the procurement varieties involved in the alliance area are the 25 winning varieties in the pilot batch collection, and the common diseases in the treatment field are still cardiovascular and cerebrovascular diseases, cancer, mental diseases, analgesia and anesthesia, asthma and diarrhea However, unlike "4 + 7", the new rules of "multiple bid winning" will be introduced in the alliance area, that is, the rules of enterprise bid winning will not be adopted According to the new regulations, the agreed purchase quantity in the first year is determined according to the following rules: if one enterprise is selected in practice, the agreed purchase quantity is 50% of the calculation base of the agreed purchase quantity in the first year; if two enterprises are selected in practice, the agreed purchase quantity is 60% of the calculation base of the agreed purchase quantity in the first year; if three enterprises are selected in practice, the agreed purchase quantity is 70% of the calculation base of the agreed purchase quantity in the first year The agreed purchase quantity of the next year is determined according to a certain proportion of the actual purchase quantity of the first year according to the type of purchase (specified specification): if one enterprise is actually selected, the agreed purchase quantity is 50% of the actual purchase quantity of the first year; if two enterprises are actually selected, the agreed purchase quantity is 60% of the actual purchase quantity of the first year; if three enterprises are actually selected, the agreed purchase quantity is 70% of the actual purchase quantity of the first year In principle, the agreed purchase quantity of the next year shall not be less than the agreed purchase quantity of the first year of the selected variety In principle, the procurement cycle of the current round is one year for the varieties of no more than two (including) selected enterprises; in principle, the procurement cycle of the current round is two years for the varieties of three selected enterprises The procurement cycle can be extended for one year depending on the actual situation It can be seen that the scope of centralized purchase is not only expanding, but also the quota of centralized purchase is expanding from one to three, and the corresponding purchase volume is also different The industry believes that in this way, it can avoid the situation that a single company is large and its production and supply cannot keep up with each other, and can maintain a balance between price and supply guarantee On the other hand, due to the increase of enterprises participating in the competition, the pressure of price reduction is great when the "track" is crowded, which will challenge the cost control ability of pharmaceutical enterprises However, in accordance with the spirit of the conference on policy ventilation of drug mining previously held in Shanghai, the principle of the second round of centralized mining is moderate bidding, multiple selection, not excessive pursuit of reduction For some small pharmaceutical companies, it may also have the opportunity to overtake in the corner Compared with the first round of procurement, there is another change, that is, the procurement subject is no longer limited to public medical institutions, which is also more favorable for enterprises and medical insurance The 25 regions of the alliance, together with the non-standard cities Hebei and Fujian that actively followed up 4 + 7 and 34 provincial administrative regions of the country, have been included in the scope of centralized procurement except for Hong Kong, Macao and Taiwan It can be predicted that with the gradual promotion and implementation of 4 + 7 in China, it is expected to further reduce the drug burden of the masses.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.